Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
OneSource Specialty Pharma (formerly Stelis Biopharma) reported Q1 FY26 consolidated revenue from operations of ₹3,272.70 million, up about 12% year-on-year from ₹2,922.89 million. On a standalone basis, revenue grew a much stronger ~34% to ₹3,210.12 million (vs ₹2,400.26 million). Consolidated loss after tax narrowed sharply to ₹(1.86) million versus ₹(55.47) million loss in Q1 FY25, while standalone swung to a profit of ₹248.15 million from a ₹239.66 million loss a year ago. The company booked an exceptional loss of ₹28.70 million linked to legal costs for the legacy Sputnik vaccine (Prestige) litigation. The company also confirmed it has fully repaid its listed non-convertible debentures. Auditor Deloitte Haskins & Sells issued an unmodified (clean) limited review conclusion.
Narrowing losses and a turnaround to standalone profit are encouraging, but the consolidated bottom line is still marginally in the red and a large Prestige BioPharma claim of USD 136.32 million (~₹1,168 crore) pending at the Singapore Arbitration Centre remains a key overhang that investors should monitor closely.